GSK plc (GSK) ORD GBP0.3125
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
EU regulators expand usage of GSK's Jemperli cancer drug
20 January 2025 07:22
(Sharecast News) - European regulators have expanded the usage of GSK's Jemperli drug for endometrial cancer, the pharmaceutical firm announced on Monday.
-
Pfizer pares back Haleon stake in £2.5bn sale
15 January 2025 08:10
(Sharecast News) - Pfizer has further reduced its holding in Haleon, it was confirmed on Wednesday, after the drugs giant offloaded 700m shares in a £2.5bn sale.
-
London close: Stocks fall, pound weakens further on rising bond yields
13 January 2025 15:19
(Sharecast News) - London stocks ended Monday in negative territory, pressured by rising bond yields and diminished expectations for near-term interest rate cuts.
-
GSK application for new Shingrix formulation accepted by FDA
10 January 2025 07:23
(Sharecast News) - GSK announced on Friday that the US Food and Drug Administration (FDA) has accepted its regulatory application for a prefilled syringe version of Shingrix, its recombinant zoster vaccine...
-
GSK cancer drug candidate gets another breakthrough designation
7 January 2025 07:22
(Sharecast News) - GSK announced on Tuesday that its investigational antibody-drug conjugate GSK'227 has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for...
-
London close: Stocks finish first week of 2025 weaker
3 January 2025 17:12
(Sharecast News) - London stock markets closed in the red on Friday as sharp declines in airline, mining, and housebuilding stocks weighed on indices, with a lack of significant news and profit-taking...
-
GSK's Nucala gets third approval in China
3 January 2025 07:12
(Sharecast News) - GSK announced on Friday that its monoclonal antibody 'Nucala', or mepolizumab, has received approval from China's National Medical Products Administration for the treatment...
-
GSK reports positive results from ovarian cancer drug trial
20 December 2024 07:12
(Sharecast News) - GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of progression free survival.
-
EU recommends expanding use of GSK endometrial cancer drug
16 December 2024 07:04
(Sharecast News) - GSK said the European Union's Committee for Medicinal Products for Human Use has recommended expanding approval of Jemperli in combination with chemotherapy for treatment of adults...
-
GSK says US agrees to look at data for new use of COPD drug
9 December 2024 07:06
(Sharecast News) - GSK said the US Food and Drug Administration has agreed to look at data from its MATINEE study to support the regulatory review process to obtain a new use of its Nucala drug as an add-on...
-
GSK extends strategic vaccine collaboration with Zhifei
5 December 2024 09:37
(Sharecast News) - Drugmaker GSK has revised and extended its strategic vaccine collaboration with Chinese firm Chongqing Zhifei Biological Products.
-
Berenberg lowers target price on GSK
2 December 2024 11:36
(Sharecast News) - Analysts at Berenberg lowered their target price on drugmaker GSK from £18.20 to £16.00 on Monday after hosting chief financial officer Julie Brown at its 2024 Pharma CFO series.
Company announcements Announcements
-
Jemperli expanded approval in the EU
20 January 2025 07:00
GSK
-
Director/PDMR Shareholding
16 January 2025 15:30
GSK
-
Director/PDMR Shareholding
15 January 2025 15:30
GSK
-
Director/PDMR Shareholding
14 January 2025 15:30
GSK
-
Director/PDMR Shareholding
13 January 2025 15:30
GSK
-
GSK enters agreement to acquire IDRx, Inc.
13 January 2025 07:00
GSK
-
Shingrix fully liquid accepted for US FDA review
10 January 2025 07:00
GSK
-
GSK ADC gets FDA breakthrough therapy designation
7 January 2025 07:00
GSK
-
GSK’s Nucala approved in China for use in CRSwNP
3 January 2025 07:00
GSK
-
Total Voting Rights
2 January 2025 15:00
GSK
-
Director/PDMR Shareholding
23 December 2024 15:30
GSK
-
Block Listing Application
20 December 2024 09:00
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.